teicoplanin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
glycopeptide antibacterials (Actinoplanes strains) 2998 61036-62-2

Description:

MoleculeDescription

Synonyms:

  • teicoplanin
  • Antibiotic 8327A
  • Antibiotic MDL 507
  • targocid
  • targosid
  • teichomycin
Lipoglycopeptide antibiotic from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety.
  • Molecular weight:
  • Formula: None
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.40 g P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 221.98 30.92 86 5179 42672 90580510
Thrombocytopenia 97.10 30.92 87 5178 208638 90414544
Multiple organ dysfunction syndrome 91.16 30.92 54 5211 68282 90554900
Stenotrophomonas infection 83.40 30.92 21 5244 2508 90620674
Septic shock 83.25 30.92 55 5210 84105 90539077
Acinetobacter infection 83.04 30.92 20 5245 1988 90621194
Pyrexia 79.26 30.92 139 5126 660346 89962836
Anaphylactic reaction 78.90 30.92 54 5211 87470 90535712
Neutropenia 76.64 30.92 79 5186 224825 90398357
Disseminated mucormycosis 62.58 30.92 13 5252 658 90622524
Renal impairment 59.20 30.92 49 5216 105372 90517810
Febrile neutropenia 58.22 30.92 58 5207 158291 90464891
Rash maculo-papular 56.27 30.92 33 5232 40900 90582282
Enterococcal infection 54.98 30.92 21 5244 9970 90613212
Toxic epidermal necrolysis 54.91 30.92 30 5235 32498 90590684
Drug resistance 53.95 30.92 29 5236 30420 90592762
Sepsis 52.09 30.92 58 5207 179756 90443426
Haemodynamic instability 51.69 30.92 21 5244 11718 90611464
Mental status changes postoperative 50.98 30.92 9 5256 189 90622993
Fungaemia 50.39 30.92 15 5250 3335 90619847
Confusion postoperative 48.85 30.92 9 5256 242 90622940
Mucormycosis 48.44 30.92 15 5250 3806 90619376
Pathogen resistance 48.06 30.92 18 5247 8097 90615085
Off label use 46.86 30.92 155 5110 1102097 89521085
Gastrointestinal mucormycosis 46.84 30.92 9 5256 305 90622877
Stevens-Johnson syndrome 46.58 30.92 26 5239 29350 90593832
Acute generalised exanthematous pustulosis 45.31 30.92 20 5245 13683 90609499
Tonsillitis bacterial 45.23 30.92 8 5257 170 90623012
Eosinophilia 44.55 30.92 25 5240 28508 90594674
Klebsiella infection 43.90 30.92 18 5247 10279 90612903
Cross sensitivity reaction 43.87 30.92 13 5252 2844 90620338
Morganella infection 43.57 30.92 10 5255 806 90622376
Haemostasis 39.09 30.92 8 5257 376 90622806
Bronchopulmonary aspergillosis 38.86 30.92 17 5248 11381 90611801
Pancytopenia 38.65 30.92 41 5224 120222 90502960
Graft versus host disease in liver 36.79 30.92 9 5256 954 90622228
Neutropenic sepsis 34.17 30.92 18 5247 18112 90605070
Rash macular 32.87 30.92 21 5244 30259 90592923
Fungal sepsis 32.59 30.92 9 5256 1532 90621650
Headache 31.57 30.92 6 5259 862740 89760442
Wound haemorrhage 31.13 30.92 10 5255 2857 90620325

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 187.04 23.62 108 7579 41967 42571681
Pyrexia 150.66 23.62 260 7427 393782 42219866
Multiple organ dysfunction syndrome 102.94 23.62 106 7581 96929 42516719
Anal inflammation 95.53 23.62 29 7658 2200 42611448
Cross sensitivity reaction 94.66 23.62 27 7660 1648 42612000
SARS-CoV-2 test negative 88.69 23.62 26 7661 1749 42611899
Thrombocytopenia 75.39 23.62 128 7559 190151 42423497
Neutropenia 72.29 23.62 129 7558 199302 42414346
Eosinophilia 69.13 23.62 53 7634 32846 42580802
Septic shock 66.12 23.62 82 7605 91590 42522058
Accident 65.25 23.62 29 7658 6474 42607174
Venoocclusive disease 64.92 23.62 25 7662 3890 42609758
Foetal cardiac arrest 64.90 23.62 10 7677 21 42613627
Rash maculo-papular 63.01 23.62 53 7634 37450 42576198
Fatigue 60.15 23.62 5 7682 435636 42178012
Geotrichum infection 54.74 23.62 14 7673 563 42613085
Systemic candida 54.26 23.62 24 7663 5295 42608353
Febrile neutropenia 53.49 23.62 109 7578 185594 42428054
Body temperature increased 49.92 23.62 36 7651 20322 42593326
Systemic mycosis 45.94 23.62 17 7670 2370 42611278
Drug resistance 44.77 23.62 42 7645 34206 42579442
Haemorrhoids 43.68 23.62 31 7656 17066 42596582
Haemophagocytic lymphohistiocytosis 41.91 23.62 31 7656 18191 42595457
Cytomegalovirus infection 41.04 23.62 39 7648 32267 42581381
Stevens-Johnson syndrome 38.59 23.62 32 7655 22146 42591502
Hyphaema 37.97 23.62 11 7676 709 42612939
Death 37.81 23.62 19 7668 471166 42142482
Fungal infection 37.57 23.62 30 7657 19692 42593956
Sepsis 37.50 23.62 99 7588 199235 42414413
Pathogen resistance 36.97 23.62 24 7663 11426 42602222
Dizziness 33.95 23.62 3 7684 249251 42364397
Drug ineffective 32.57 23.62 209 7478 629988 41983660
Respiratory gas exchange disorder 32.16 23.62 9 7678 512 42613136
Cellulitis 31.99 23.62 47 7640 61538 42552110
Toxic skin eruption 30.77 23.62 23 7664 13707 42599941
Encephalitis brain stem 30.73 23.62 7 7680 171 42613477
C-reactive protein increased 28.07 23.62 45 7642 63515 42550133
Acute generalised exanthematous pustulosis 27.70 23.62 18 7669 8577 42605071
Acute kidney injury 27.66 23.62 135 7552 367202 42246446
Brain abscess 27.34 23.62 14 7673 4270 42609378
Thrombotic microangiopathy 27.12 23.62 22 7665 14760 42598888
Infective aneurysm 25.87 23.62 9 7678 1050 42612598
Pancytopenia 25.77 23.62 62 7625 117681 42495967
Hepatotoxicity 25.72 23.62 27 7660 25140 42588508
Mast cell degranulation present 24.71 23.62 5 7682 68 42613580
Weight decreased 24.63 23.62 4 7683 207944 42405704
Renal impairment 24.08 23.62 58 7629 110170 42503478

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 393.00 23.86 192 12816 81903 110494388
Pyrexia 233.47 23.86 394 12614 897871 109678420
Multiple organ dysfunction syndrome 194.31 23.86 153 12855 151557 110424734
Thrombocytopenia 174.99 23.86 210 12798 348675 110227616
Neutropenia 155.23 23.86 205 12803 374415 110201876
Septic shock 150.16 23.86 134 12874 157394 110418897
Cross sensitivity reaction 125.21 23.86 40 12968 5527 110570764
Rash maculo-papular 119.69 23.86 86 12922 74136 110502155
Eosinophilia 119.15 23.86 78 12930 57858 110518433
Febrile neutropenia 112.48 23.86 161 12847 316606 110259685
Acinetobacter infection 111.45 23.86 33 12975 3540 110572751
Anal inflammation 99.94 23.86 28 12980 2468 110573823
Sepsis 91.60 23.86 149 12859 327197 110249094
SARS-CoV-2 test negative 90.08 23.86 25 12983 2128 110574163
Drug resistance 87.85 23.86 64 12944 56310 110519981
Fatigue 86.27 23.86 19 12989 1215939 109360352
Anaphylactic reaction 85.39 23.86 85 12923 114215 110462076
Geotrichum infection 79.03 23.86 20 12988 1192 110575099
Stenotrophomonas infection 76.45 23.86 28 12980 5830 110570461
Systemic mycosis 71.89 23.86 24 12984 3805 110572486
Toxic skin eruption 71.53 23.86 43 12965 27472 110548819
Stevens-Johnson syndrome 70.26 23.86 52 12956 46849 110529442
Acute generalised exanthematous pustulosis 67.28 23.86 38 12970 21626 110554665
Renal impairment 65.63 23.86 95 12913 188350 110387941
Venoocclusive disease 63.54 23.86 25 12983 6325 110569966
Enterococcal infection 61.30 23.86 35 12973 20331 110555960
Pathogen resistance 60.35 23.86 33 12975 17639 110558652
Drug ineffective 59.60 23.86 342 12666 1520198 109056093
Accident 59.53 23.86 28 12980 10924 110565367
Disseminated mucormycosis 59.44 23.86 18 12990 2084 110574207
Haemophagocytic lymphohistiocytosis 58.85 23.86 40 12968 31519 110544772
Acute kidney injury 58.80 23.86 186 12822 635244 109941047
Toxic epidermal necrolysis 57.45 23.86 50 12958 56677 110519614
Pancytopenia 56.64 23.86 94 12914 209519 110366772
Systemic candida 55.76 23.86 26 12982 9948 110566343
Dizziness 53.43 23.86 9 12999 698184 109878107
Off label use 52.06 23.86 327 12681 1499858 109076433
Fungal infection 51.89 23.86 45 12963 50761 110525530
Fungaemia 50.69 23.86 21 12987 6065 110570226
Cytomegalovirus infection 49.20 23.86 45 12963 54399 110521892
Headache 43.44 23.86 25 12983 882352 109693939
Haemodynamic instability 42.65 23.86 29 12979 22859 110553432
Klebsiella infection 41.26 23.86 27 12981 19982 110556309
Weight decreased 40.67 23.86 4 13004 468053 110108238
Cellulitis 40.20 23.86 61 12947 125955 110450336
Fall 39.61 23.86 11 12997 603471 109972820
Mucormycosis 39.51 23.86 21 12987 10607 110565684
Cholestasis 39.22 23.86 43 12965 64475 110511816
Mental status changes postoperative 38.31 23.86 8 13000 201 110576090
Platelet count decreased 38.24 23.86 84 12924 230359 110345932
Hyphaema 37.94 23.86 11 12997 1096 110575195
Joint swelling 37.91 23.86 4 13004 442841 110133450
Haemorrhoids 37.24 23.86 32 12976 35640 110540651
Tonsillitis bacterial 36.98 23.86 8 13000 239 110576052
Bronchopulmonary aspergillosis 35.76 23.86 29 12979 29834 110546457
Dermatitis exfoliative 35.49 23.86 20 12988 11327 110564964
Candida infection 34.53 23.86 35 12973 47974 110528317
Drug intolerance 33.97 23.86 4 13004 406508 110169783
Confusion postoperative 33.80 23.86 8 13000 360 110575931
Gastrointestinal mucormycosis 32.83 23.86 9 12999 732 110575559
Brain abscess 32.80 23.86 16 12992 6758 110569533
Nasopharyngitis 32.65 23.86 4 13004 394357 110181934
Abdominal discomfort 32.60 23.86 4 13004 393854 110182437
Alopecia 31.98 23.86 3 13005 364750 110211541
Fusarium infection 31.60 23.86 12 12996 2759 110573532
Morganella infection 31.38 23.86 10 12998 1369 110574922
Hepatotoxicity 31.37 23.86 38 12970 63362 110512929
C-reactive protein increased 31.25 23.86 75 12933 217844 110358447
Respiratory gas exchange disorder 31.11 23.86 9 12999 889 110575402
Hyperbilirubinaemia 30.97 23.86 27 12981 30644 110545647
Body temperature increased 30.74 23.86 35 12973 54678 110521613
Posterior reversible encephalopathy syndrome 30.61 23.86 28 12980 33833 110542458
Haemostasis 30.52 23.86 8 13000 548 110575743
Thrombotic microangiopathy 30.12 23.86 26 12982 29123 110547168
Shock 29.63 23.86 34 12974 53554 110522737
Graft versus host disease in liver 29.29 23.86 11 12997 2454 110573837
Encephalitis brain stem 28.96 23.86 7 13001 345 110575946
Agranulocytosis 28.92 23.86 36 12972 61724 110514567
Arthralgia 27.22 23.86 31 12977 779601 109796690
Graft versus host disease in skin 27.04 23.86 15 12993 8239 110568052
Device related infection 26.95 23.86 28 12980 39491 110536800
Staphylococcal infection 26.89 23.86 37 12971 69907 110506384
Mast cell degranulation present 26.85 23.86 5 13003 68 110576223
Asthenia 26.76 23.86 25 12983 688974 109887317
Pain in extremity 26.62 23.86 12 12996 487106 110089185
Infective aneurysm 26.62 23.86 9 12999 1483 110574808
Dyspnoea 26.32 23.86 57 12951 1106815 109469476
Acute myeloid leukaemia 25.98 23.86 27 12981 38083 110538208
Graft versus host disease in gastrointestinal tract 25.88 23.86 15 12993 8953 110567338
Cytokine release syndrome 25.25 23.86 36 12972 70270 110506021
Rash erythematous 25.23 23.86 39 12969 81793 110494498
Liver abscess 25.18 23.86 14 12994 7725 110568566
Weight increased 25.11 23.86 9 12999 419635 110156656
Depression 24.44 23.86 4 13004 317331 110258960
Cardiac arrest 24.31 23.86 64 12944 196689 110379602

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01XA02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Glycopeptide antibacterials
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:36047 antibacterial drug

Related Drugs by ATC class:

J01XA Glycopeptide antibacterials 4 drugs
dalbavancinoritavancintelavancinvancomycin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Staphylococcal infectious disease indication 56038003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4025272 VUID
N0000171799 NUI
D02142 KEGG_DRUG
4025272 VANDF
C0145106 UMLSCUI
CHEBI:29687 CHEBI
CHEMBL4297166 ChEMBL_ID
D017334 MESH_DESCRIPTOR_UI
DB06149 DRUGBANK_ID
10924 IUPHAR_LIGAND_ID
5155 INN_ID
4U3D3YY81M UNII
133065662 PUBCHEM_CID
196469 RXNORM
003765 NDDF
387529008 SNOMEDCT_US
96014005 SNOMEDCT_US

Pharmaceutical products:

None